Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company will participate in the following
- Results of long-term treatment from the ITCH and IMAGINE II studies presented in late-breaking oral presentation at AASLD - Data demonstrates significant and durable improvements in pruritus in children with Alagille syndrome through 220 weeks of maralixibat treatment - Results have been included
Maralixibat data highlights the relationship between the reduction of serum bile acids and pruritus intensity, improved growth, and other quality of life measures. Analysis of the natural variability of pruritus in children with Alagille syndrome demonstrates persistent severity.
- Initiated rolling NDA submission and launched Expanded Access Program for maralixibat in Alagille syndrome. - Presented five-year transplant-free survival data for patients with PFIC2 at Digital International Liver Congress (EASL). - European Marketing Authorization Application submission for